Compare · ASTC vs BIO
ASTC vs BIO
Side-by-side comparison of Astrotech Corporation (DE) (ASTC) and Bio-Rad Laboratories Inc. (BIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASTC and BIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $7.76B, about 268.2x ASTC ($28.9M).
- Over the past year, ASTC is up 163.6% and BIO is up 25.9% - ASTC leads by 137.7 points.
- ASTC has hit the wire 6 times in the past 4 weeks while BIO has been quiet.
- BIO has more recent analyst coverage (12 ratings vs 0 for ASTC).
- Company
- Astrotech Corporation (DE)
- Bio-Rad Laboratories Inc.
- Price
- $15.71-6.77%
- $290.15+0.43%
- Market cap
- $28.9M
- $7.76B
- 1M return
- +516.08%
- +17.09%
- 1Y return
- +163.59%
- +25.88%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 1980
- News (4w)
- 6
- 0
- Recent ratings
- 0
- 12
Astrotech Corporation (DE)
Astrotech Corporation operates as a science and technology development and commercialization company worldwide. It operates through three segments, Astrotech Technologies, Inc. (ATI), 1st Detect Corporation (1st Detect), and AgLAB Inc (AgLAB). The ATI segment owns and licenses the AMS Technology, the platform mass spectrometry technology. The 1st Detect segment manufactures explosives and narcotics trace detectors for use at airports, secured facilities, and borders. This segment provides TRACER 1000, a mass spectrometer based explosives trace detector to replace the explosives trace detectors used at airports, cargo and secured facilities, and borders. The AgLAB segment develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. It also develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. Astrotech Corporation was incorporated in 1984 is based in Austin, Texas.
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest ASTC
- Astrotech Corporation (DE) filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Astrotech Board Approves Potential Sale Process of 1st Detect and TRACER 1000, the Only Field-Deployed Mass Spectrometry ETD, as the Company Focuses on Its Initiative in Space
- Astrotech Corporation's 1st Detect TRACER 1000 Receives ECAC Certification for Wand Swabbing
- Astrotech Corporation (DE) filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by Astrotech Corporation (DE)
- Astrotech Corporation Board of Directors Approves Strategic Lunar Resource and Infrastructure Initiative to Advance Future Moon-Based Quantum Computing Manufacturing
- Director Wilkinson Tom was granted 6,006 shares, increasing direct ownership by 25% to 29,868 units (SEC Form 4)
- EN-SCAN Launches Labrador HH-GC, Engineered to Deliver Laboratory-Grade VOC Analysis Directly in the Field
- Director Winn Charles Arch was granted 6,006 shares, increasing direct ownership by 154% to 9,895 units (SEC Form 4)
- Director Halinski John William was granted 6,006 shares, increasing direct ownership by 200% to 9,006 units (SEC Form 4)
Latest BIO
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025